Half-life questions become easier when you separate three things: how quickly concentration changes, how a medicine reaches its new equilibrium, and whether the patient's elimination conditions have remained constant. A remembered number of days is not enough when an interacting medicine, a change in smoking or acute illness has altered the situation.
This is a pharmacokinetic reasoning tutorial for MRCPsych Paper A, not a prescribing schedule. All numerical examples and diagrams are fictional teaching models created in September 2026. No administered doses are supplied. The IUPHAR Pharmacology Education Project provides the underlying distinction between absorption, distribution, metabolism and excretion; medicine-specific decisions require current product information.
Translate a concentration-time graph
Start with the axes. A graph may show a measured plasma concentration, a proportion of a previous concentration or an average concentration over time. These are not interchangeable. A rising line can reflect continued absorption or repeated input rather than a failure of elimination.
For a simple first-order elimination model, the same fraction disappears in each equal time interval. A zero-order model instead removes a constant amount over an interval. The first-order assumption makes the following original normalised graph possible:
Concentration remaining after input has stopped
100% | *
75% |
50% | *
25% | *
12.5%| *
6.25%| *
+---------------------------
0 1 2 3 4
Elapsed elimination half-lives
This sketch excludes continuing absorption, active metabolites and changes in clearance. It represents a model, not the expected clinical recovery of a person taking a particular psychotropic medicine. A plasma half-life also does not, by itself, specify how long a receptor effect, withdrawal symptom or adverse effect will last.
Before calculating, ask whether the question supplies a terminal elimination half-life, a formulation-specific time course or a clinical duration of effect. Answer the quantity requested rather than treating all three as synonyms.
Half-life and accumulation through a worked example
Calculation one: disappearance. A hypothetical substance has a constant elimination half-life of 24 hours, and there is no further input. After 72 hours, three half-lives have elapsed. The fraction remaining is (1/2)^3 = 0.125, or 12.5% of the starting concentration. Saying that the substance is completely absent would be incorrect.
Calculation two: approach to equilibrium. Under constant input and the same linear model, the fraction of the eventual steady-state concentration reached after three half-lives is 1 - (1/2)^3 = 0.875, or 87.5%. That is not a prediction of symptom improvement or a target for changing treatment.
Approach to the eventual steady-state concentration
100% | ........
96.9%| *
93.8%| *
87.5%| *
75% | *
50% | *
0% | *
+--------------------------------
0 1 2 3 4 5
Elapsed elimination half-lives
The graph approaches an asymptote: five half-lives does not mean an exact mathematical finish. Intermittent administration produces peaks and troughs around a repeating pattern, rather than necessarily producing one flat concentration. The statement that a patient has reached steady state concerns that repeating exposure pattern under unchanged conditions.
Calculation three: a specified fraction. To reach 90% of the eventual concentration in this model, solve (1/2)^n = 0.10. The answer is approximately 3.32 half-lives. With the fictional 24-hour half-life, that is about 79.7 hours. This exercise demonstrates why a requested percentage should be calculated rather than replaced with a memorised slogan.
Clearance, volume of distribution and the time course
Clearance is expressed as a volume per unit time. Apparent volume of distribution relates the amount in the body to the measured plasma concentration; it is not a literal anatomical compartment that must fit inside the body. These definitions are set out in IUPHAR's pharmacology glossary.
In the simplified one-compartment, first-order model, elimination half-life equals 0.693 x apparent volume of distribution / clearance. The units must cancel to a unit of time.
Calculation four: changing elimination. Let apparent volume of distribution be 100 L and clearance be 5 L/hour. Half-life is 0.693 x 100 / 5 = 13.86 hours. If clearance falls to 2.5 L/hour while the apparent volume remains unchanged, half-life becomes 27.72 hours. The prediction depends on the stated assumption that only clearance changes.
Loading and maintenance answer different conceptual questions. Establishing an initial concentration relates to distribution and bioavailability; sustaining exposure relates to ongoing elimination. A change in renal or hepatic function therefore cannot be translated into a universal rule to change every component of a regimen in the same way. Check the medicine, formulation, indication and patient rather than applying a generic numerical shortcut.
Enzyme inhibition and induction over time
Identify the substrate, the interacting medicine or exposure, and the relevant pathway. Then ask whether the parent substance is active, whether active metabolites matter and whether there are alternative elimination routes. An interaction label is the beginning of the explanation, not the final answer.
The following examples describe published product information checked on 27 September 2026, not instructions to adjust a prescription:
| Published example | Directional concern | What still needs checking |
|---|---|---|
| Fluvoxamine inhibits enzymes including CYP1A2 and CYP2C19 | Exposure to a susceptible substrate may increase | The exact substrate, interaction strength and clinical consequence |
| Olanzapine with smoking or an inducing medicine | Metabolism can increase and exposure can fall | Whether the exposure has started, stopped or changed |
| Agomelatine with fluvoxamine or ciprofloxacin | Strong CYP1A2 inhibition creates a clinically important interaction | The product information lists this combination as contraindicated |
The sources are the fluvoxamine SmPC, olanzapine SmPC and agomelatine SmPC. An enzyme table should never replace checking the actual combination.
In an original examination-style scenario, a patient has been stable on a substrate medicine and then starts an inhibitor. The defensible first prediction is a possible rise in substrate exposure, subject to the pathways involved. It is not that toxicity must occur immediately, or that the interacting medicine simply adds a separate sedative effect. Pharmacokinetic and pharmacodynamic interactions can coexist.
Smoking, illness and changing patient factors
A stable historical prescription does not guarantee stable current exposure. The MHRA's clozapine toxicity advice, reviewed for this article on 27 September 2026, identifies circumstances including smoking changes, infection and interacting medicines in which blood-concentration monitoring may be important.
Consider a fictional patient admitted to hospital who stops smoking and develops a significant infection. New drowsiness should not automatically be attributed to the psychiatric illness, the unfamiliar environment or one normal blood-count result. Establish the treatment and smoking timeline, assess the patient and seek appropriate specialist review. A blood concentration and a blood count answer different questions.
Do not confuse tobacco-smoke exposure with nicotine alone when explaining enzyme induction. Similarly, the return to smoking after discharge is another exposure change, not a return to an irrelevant lifestyle detail. The clinical clozapine decisions belong in iatroX's dedicated monitoring article; this tutorial explains why the time course matters.
Make the reasoning visible in your answer
Use a short sequence: name the measured quantity, state the model, calculate with units, predict the direction of change, and identify the assumption most likely to fail. A calculation can be mathematically correct while the model is clinically inappropriate.
For practice, change just one dependency in the fictional examples: clearance, distribution, continued input or sampling time. Explain what should change before looking at the new result. Per iatroX product information, September 2026, the Socratic Tutor can open on an attempted question and ask targeted follow-ups; its usefulness here is exposing the mistaken assumption, not authorising a treatment adjustment.
Frequently asked questions
Does five half-lives mean a medicine has completely disappeared?
No. In a simple first-order model without further input, about 3.1% of the original concentration remains after five half-lives, and actual medicines may have more complex time courses.
Is half-life the same as the duration of clinical effect?
No. Active metabolites, receptor effects, formulation and the patient's response can separate the measured plasma time course from the duration of benefit or harm.
Can an enzyme-interaction table tell me the correct prescribing change?
No. It helps predict a possible mechanism, but the exact medicine combination, current product information and individual clinical assessment determine the appropriate action.